Health ❯ Healthcare ❯ Patient Care

Treatment Outcomes

Survival Rates Progression-Free Survival Quality of Life Adverse Events Adverse Effects Survivorship Personalized Medicine Clinical Response Functional Capacity Clinical Efficacy

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

The FDA review sets a clear path for a potential label expansion pending a decision in early 2027.

CRISPR CD33-Deleted Stem Cell Transplant Shows Early Promise for AML and MDS

Erasca Shares Plunge After Trial Death and Patent Challenge

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

NEJM Publication Confirms Phase 3 Win for Brepocitinib in Dermatomyositis

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

NHS England Lowers Bowel Screening FIT Trigger to 80µg Hb/g Next Month

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

Janux Plunges on Mixed Phase 1 Prostate Cancer Data for JANX007

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer